Charles Nemeroff

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Charles Barnet Nemeroff (born 1949) is an American psychiatrist known for his work in treating depression.

Life and career[edit]

Nemeroff was born in New York City and graduated from the City College of New York in 1970. He received a Master’s degree in Biology in 1973 from Northeastern University. He then earned his PhD in neurobiology in 1973 and his M.D. in 1981, both from the University of North Carolina at Chapel Hill.

Nemeroff joined the faculty of Duke University after completing his training, then took a position at the Emory University School of Medicine in 1991. He is the author of numerous textbooks, papers, and clinical studies.

Nemeroff later moved to Florida and become the chair of psychiatry at the University of Miami.[1]

Diathesis-stress model[edit]

Nemeroff proposed a diathesis-stress model of clinical depression, which suggests that depression is caused by a combination of "vulnerability genes", "resistance genes", and early adverse life events.[2]

Ethical violations[edit]

Nemeroff's undisclosed ties to drugmakers and under-reported incomes from them have raised questions about conflict of interest.[3][4] Following a congressional investigation, Nemeroff was found to be in violation of some federal and university regulations and resigned as chair of the psychiatry department at Emory University.[5][6][7] He was also forbidden by Emory to act as an investigator or co-investigator on National Institutes of Health grants for at least two years.

According to the Annals of Neurology, the court documents released as a result of one of the lawsuits against GSK in October 2008 indicated that GSK "and/or researchers may have suppressed or obscured suicide risk data during clinical trials" of paroxetine. Nemeroff stepped down as department chair amid revelations that he had received over $960,000 from GSK in 2006, yet reported less than $35,000 to Emory University. Subsequent investigations revealed payments totaling more than $2.5 million from drug companies between 2000 and 2006, yet only a fraction was disclosed.[8] In July 2012, GlaxoSmithKline pleaded guilty to criminal charges.[9] The settlement is related to the company's illegal promotion of prescription drugs, its failure to report safety data, bribing doctors and using kickback schemes.[10][11][12][13]

See also[edit]

References[edit]

  1. ^ Nature News
  2. ^ "NEUROBIOLOGICAL ALTERATIONS THAT RESULT FROM EARLY LIFE TRAUMA". Medscape. 
  3. ^ Petersen, Melody (August 3, 2003). Undisclosed Financial Ties Prompt Reproval of Doctor. New York Times
  4. ^ Harris, Gardiner (October 3, 2008). Top Psychiatrist Failed to Report Drug Income. New York Times
  5. ^ Statement from Emory University. Atlanta Journal-Constitution
  6. ^ Gellene, Denise and Thomas H. Maugh II (October 4, 2008). Emory University psychiatrist accused of conflict of interest. Los Angeles Times
  7. ^ Kirk, Stuart A. (2013). Mad Science: Psychiatric Coercion, Diagnosis, and Drugs. Transaction Publishers. p. 21. 
  8. ^ Samson K (December 2008). "Senate probe seeks industry payment data on individual academic researchers". Annals of Neurology 64 (6): A7–9. doi:10.1002/ana.21271. PMID 19107985. 
  9. ^ "GlaxoSmithKline". BBC News. 4 July 2012. 
  10. ^ Fred Mogul (2 July 2012). "NY to Get Millions in GlaxoSmithKlein Settlement". WNYC. Retrieved 2 July 2012. 
  11. ^ "BBC News -GlaxoSmithKline to pay $3bn in US drug fraud scandal". BBC Online. 2012-07-02. Retrieved 2 July 2012. 
  12. ^ Thomas, Katie and Schmidt, Michael S. (July 2, 2012). "Glaxo Agrees to Pay $3 Billion in Fraud Settlement". The New York Times. Retrieved July 3, 2012. 
  13. ^ "GlaxoSmithKline Agrees to Pay $3 Billion in U.S. Drug Settlement". Bloomberg. 2 July 2012.